Skip to main content
Article thumbnail
Location of Repository

Plasma gelsolin as a biomarker of inflammation

By Mark J DiNubile


The prognostic implications of declining plasma gelsolin levels have been documented after a diverse variety of acute insults. Because gelsolin concentrations fall prior to the development of complications, a pathophysiological role for gelsolin depletion has been postulated in delayed multiorgan failure. The original hypothesis about the function of circulating gelsolin was that it scavenged actin released from cells at the site of injury. Although extracellular actin may be the primary cause of gelsolin depletion, the biologic imperative for gelsolin could entail the modulation of several inflammatory mediators as much as the disposal of actin. Translational research is actively addressing whether replenishment of plasma gelsolin could provide an efficacious and well tolerated therapeutic intervention in selected seriously ill patients

Topics: Editorial
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther
  2. (2002). DiNubile MJ: Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice.
  3. (1999). DiNubile MJ: Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med
  4. (2008). Janmey PA: Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components.
  5. (2005). Janmey PA: Inactivation of endotoxin by human plasma gelsolin. Biochemistry
  6. (2002). JH: Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood
  7. (2008). PA: Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders.
  8. (2006). SO: Relationship of plasma gelsolin levels in outcomes of critically ill surgical patients. Ann Surg
  9. (2007). Stossel TP: Modifications of cellular responses to lysophosphatidic acid and platelet activating factor by plasma gelsolin.
  10. (2007). Stossel TP: Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med
  11. (1992). The extracellular actin-scavenger system and actin toxicity.
  12. (2004). Turnage RH: Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.